Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
7 min read
InduPro, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
InduPro, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
8 min read
Immatics Biotechnologies GmbH Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Immatics Biotechnologies GmbH 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
Ingenium Therapeutics Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Ingenium Therapeutics Co., Ltd. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
8 min read
InnoLake Pharmaceuticals (Hangzhou) Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
InnoLake Pharmaceuticals (Hangzhou) Co., Ltd. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
IconOVir Bio, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
IconOVir Bio, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
8 min read
I-MAB Biopharma Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
I-MAB Biopharma Co., Ltd. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
IGI Therapeutics SA Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
IGI Therapeutics SA 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
8 min read
Ichnos Glenmark Innovation, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Ichnos Glenmark Innovation, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
HitGen, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
HitGen, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
Hetero Drugs Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Hetero Drugs Ltd. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
HLB Pep Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
HLB Pep Co., Ltd. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
Hygieia Pharmaceuticals Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Hygieia Pharmaceuticals Co., Ltd. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
<
1
<<
978
979
980
981
982
>>
2260
>